Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1825076 | 0.90 | HRH3 (0.42) | HRH3PDE7AABCB1NPC1RAB9A | |
| SCHEMBL16065953 | 0.90 | HRH3 (0.39) | HRH3PDE7AABCB1NPC1RAB9A | |
| SCHEMBL10190128 | 0.86 | KDM4E (0.39) | HRH3ABCB1IKZF2KMT2ACYP2D6 | |
| SCHEMBL8266529 | 0.86 | HRH3 (0.38) | HRH3CYP2D6CHRM1 | |
| SCHEMBL16622453 | 0.85 | PDE7A (0.37) | HRH3PDE7AIRAK4 | |
| SCHEMBL24294895 | 0.85 | HRH3 (0.40) | HRH3PDE7AABCB1IKZF2CYP2D6 | |
| SCHEMBL18034123 | 0.85 | HRH3 (0.43) | HRH3ABCB1CYP2D6CYP2C19 | |
| SCHEMBL10190130 | 0.84 | CHRM1 (0.33) | HRH3IKZF2CHRM1 | |
| SCHEMBL233141 | 0.84 | CHRM2 (0.37) | HRH3KMT2ACYP2D6CHRM1 | |
| SCHEMBL5857613 | 0.84 | HRH3 (0.34) | HRH3PDE7ANPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3892276-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10947217-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3448386-B1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20200299263-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20190256494-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| US-9951048-B1 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170313682-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2017-11-02 | — | — | US | disclosed |
| WO-2017189829-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2017-11-02 | — | — | WO | disclosed |
| US-9718825-B2 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2017-08-01 | — | — | US | disclosed |
| EP-2970259-B1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-12-21 | — | — | EP | disclosed |
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-01-28 | — | — | US | disclosed |
| WO-2014140065-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299263-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | HRH3 2318/4885PDE7A 3919/4885ABCB1 1910/4885 |
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | HRH3 2327/4885PDE7A 1841/4885ABCB1 2010/4885 |
| US-10947217-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | HRH3 2318/4885PDE7A 3919/4885ABCB1 1910/4885 |
| US-20190256494-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | HRH3 926/4885PDE7A 394/4885ABCB1 2328/4885 |
| US-20170313682-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | HRH3 2318/4885PDE7A 3919/4885ABCB1 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.